Sign in Register

Ceftazidime (ceftazidime)

Advertisement

Last reviewed · Source: First Databank (FDB) drug data

Overview

Ceftazidime is a semisynthetic, third generation cephalosporin antibiotic.

Ceftazidime is used for the treatment of bone and joint infections, intra-abdominal and gynecologic infections, meningitis and other CNS infections, lower respiratory tract infections, skin and skin structure infections, septicemia, and complicated or uncomplicated urinary tract infections caused by susceptible bacteria. The drug also is used for empiric anti-infective agent therapy in febrile neutropenic patients+ and has been used for perioperative prophylaxis+.

Generic name: ceftazidime
Pronunciation: (sef-TAZ-i-deem)

Reference product & biosimilars

No reference, biosimilar or interchangeable associated with this drug.

Today’s intelligence on Ceftazidime

Intelligence content is not available yet.

Indications

The following indications are listed for Ceftazidime:

  • Acute Pseudomonas Aeruginosa Pneumonia Associated With Cystic Fibrosis
  • Bacterial Meningitis
  • Bacterial Pneumonia
  • Bacterial Sepsis
  • Bacterial Urinary Tract Infection
  • Bone Infection
  • Citrobacter Pneumonia
  • Complicated E. Coli Uti
  • Complicated Proteus Uti
  • Complicated Uti With Pseudomonas Aeruginosa
  • E. Coli Cervicitis
  • E. Coli Endometritis
  • E. Coli Gynecological Infections
  • E. Coli Pelvic Cellulitis
  • E. Coli Pelvic Inflammatory Disease
  • E. Coli Peritonitis
  • E. Coli Septicemia
  • E. Coli Urinary Tract Infection
  • Ecthyma Gangrenosum
  • Endometritis
  • Enterobacter Cloacae Urinary Tract Infection
  • Enterobacter Complicated Uti
  • Enterobacter Joint Infection
  • Enterobacter Osteomyelitis
  • Enterobacter Pneumonia
  • Escherichia Coli Pneumonia
  • Febrile Neutropenic Patient Presumed Infection Treatment
  • H. Influenzae Meningitis
  • Haemophilus Influenzae Pneumonia
  • Haemophilus Septicemia
  • Infectious Disease Of Abdomen
  • Infectious Disorder Of Joint
  • Inflammatory Disease Of Female Pelvic Organs
  • Klebsiella Complicated Uti
  • Klebsiella Joint Infection
  • Klebsiella Pneumonia
  • Klebsiella Pneumoniae Osteomyelitis
  • Klebsiella Pneumoniae Peritonitis
  • Klebsiella Pneumoniae Septicemia
  • Klebsiella Urinary Tract Infection
  • Lower Respiratory Infection
  • Meningococcal Meningitis
  • Neonatal Meningitis
  • Peritonitis
  • Proteus Pneumonia
  • Proteus Urinary Tract Infection
  • Pseudomonas Aeruginosa Joint Infection
  • Pseudomonas Aeruginosa Osteomyelitis
  • Pseudomonas Aeruginosa Pneumonia
  • Pseudomonas Aeruginosa Septicemia
  • Pseudomonas Aeruginosa Urinary Tract Infection
  • Sepsis Caused By Serratia
  • Skin And Skin Structure E. Coli Infection
  • Skin And Skin Structure Enterobacter Infection
  • Skin And Skin Structure Infection
  • Skin And Skin Structure Klebsiella Infection
  • Skin And Skin Structure Proteus Infection
  • Skin And Skin Structure Pseudomonas Aeruginosa Infection
  • Skin And Skin Structure Serratia Infection
  • Skin And Skin Structure Streptococcus Pyogenes Infection
  • Staphylococcal Pneumonia
  • Staphylococcus Aureus Joint Infection
  • Staphylococcus Aureus Osteomyelitis
  • Staphylococcus Aureus Septicemia
  • Staphylococcus Aureus Skin And Skin Structure Infection
  • Staphylococcus Peritonitis
  • Streptococcal Pneumonia
  • Streptococcal Septicemia

Also known as: Bacteremia With Sepsis, Bacterial Septicemia, Cervicitis Due To E. Coli, Cervicitis Due To Escherichia Coli, Complicated Pseudomonas Aeruginosa Urinary Tract Infection, Complicated Urinary Tract Infection Due To Aerobacter, Complicated Urinary Tract Infection Due To Enterobacter, Complicated Urinary Tract Infection Due To Escherichia Coli, Complicated Urinary Tract Infection Due To Klebsiella, Complicated Urinary Tract Proteus Species Infection, Complicated Uti Due To E. Coli, Complicated Uti Due To Enterobacter Species, Complicated Uti Due To Klebsiella Species, Complicated Uti Due To Proteus Species, Complicated Uti Due To Pseudomonas Aeruginosa, Dermatitis Gangrenosa Infantum, Disseminated Cutaneous Gangrene, E. Coli Gynecologic Infection, E. Coli Pneumonia, E. Coli Sepsis, E. Coli Uti, Empiric Therapy In Febrile Neutropenia, Empiric Therapy Of Infection In Febrile Neutrophilic Leukocytopenia, Empiric Therapy Of Infection In Febrile Neutrophilopenia, Endometritis Due To E. Coli, Endometritis Due To Escherichia Coli, Escherichia Coli Sepsis, Escherichia Coli Septicemia, Gynecologic Infection Due To E. Coli, Gynecologic Infection Due To Escherichia Coli, H. Flu Meningitis, H. Flu Pneumonia, H. Influenzae Pneumonia, Haemophilus Influenzae Meningitis, Hemophilus Influenzae Pneumonia, Infection Of Skin And/Or Subcutaneous Tissue, Infection Of The Lungs Due To Enterobacter, Infection Of The Lungs Due To Pseudomonas Aeruginosa, Influenza Bacillus Pneumonia, Influenzae Bacillus Meningitis, Intra-Abdominal Infection, Joint Infection, Joint Infection Due To Enterobacter Species, Joint Infection Due To Klebsiella Species, Joint Infection Due To Pseudomonas Aeruginosa, Joint Infection Due To Staphylococcus Aureus, Joint Infection Due To Staphylococcus Pyogenes Aureus, Klebsiella Spp. Septic Arthritis, Klebsiella Uti, Lower Respiratory Tract Infection, Meningitis Due To Haemophilus Influenzae, Meningitis Due To Hemophilus Influenzae, Osteomyelitis Due To Aerobacter, Osteomyelitis Due To Enterobacter, Osteomyelitis Due To Enterobacter Species, Osteomyelitis Due To Klebsiella Pneumoniae, Osteomyelitis Due To Pseudomonas Aeruginosa, Osteomyelitis Due To Staphylococcus Aureus, Osteomyelitis Due To Staphylococcus Pyogenes Aureus, Parametritis Due To Escherichia Coli, Pelvic Cellulitis Due To E. Coli, Pelvic Cellulitis Due To Escherichia Coli, Pelvic Inflammatory Disease Due To E. Coli, Pelvic Inflammatory Disease Due To Escherichia Coli, Peritonitis Due To Escherichia Coli, Peritonitis Due To Klebsiella Pneumoniae, Peritonitis Due To Staphylococcus Species, Pfeiffer's Bacillus Meningitis, Pfeiffer's Bacillus Pneumonia, Pid Due To Escherichia Coli, Pneumonia Due To Citrobacter Species, Pneumonia Due To E. Coli, Pneumonia Due To Escherichia Coli, Pneumonia Due To Haemophilus Influenzae, Pneumonia Due To Klebsiella Species, Pneumonia Due To Klebsiella Spp., Pneumonia Due To Proteus Species, Pneumonia Due To Pseudomonas Aeruginosa, Pneumonia Due To Staphylococcus Species, Pneumonia Due To Staphylococcus Spp., Pneumonia Due To Streptococcus Species, Pneumonia Due To Streptococcus Spp., Presumed Infection In Febrile Neutropenic Patient, Proteus Spp. Pneumonia, Pyogenic Bone Infection Due To Enterobacter, Pyogenic Bone Infection Due To Klebsiella Pneumoniae, Pyogenic Bone Infection Due To Pseudomonas Aeruginosa, Pyogenic Bone Infection Due To Staphylococcus Aureus, Sepsis Due To Haemophilus Species, Sepsis Due To Klebsiella Pneumoniae, Sepsis Due To Pseudomonas Aeruginosa, Sepsis Due To Serratia Spp., Sepsis Due To Staphylococcus Aureus, Septicemia Due To Haemophilus Species, Septicemia Due To Haemophilus Spp., Septicemia Due To Hemophilus Species, Septicemia Due To Klebsiella Pneumoniae, Septicemia Due To Pseudomonas Aeruginosa, Septicemia Due To Staph Aureus, Septicemia Due To Staphylococcus Aureus, Serratia Sepsis, Skin & Skin Soft Tissue Streptococcus Pyogenes Infection, Skin And Skin Soft Tissue Enterobacter Infection, Skin And Skin Soft Tissue Escherichia Coli Infection, Skin And Skin Soft Tissue Infection Due To Aerobacter, Skin And Skin Soft Tissue Infection Due To Enterobacter, Skin And Skin Soft Tissue Infection Due To Klebsiella, Skin And Skin Soft Tissue Infection Due To Serratia, Skin And Skin Soft Tissue Proteus Infection, Skin And Skin Soft Tissue Pseudomonas Aeruginosa Infection, Skin And Skin Soft Tissue Staphylococcus Aureus Infection, Skin And Soft Tissue Skin Infection, Staphylococcal Peritonitis, Streptococcal Sepsis, Trachelitis Due To E. Coli, Urinary Tract Infection Due To Enterobacter Cloacae, Urinary Tract Infection Due To Escherichia Coli, Urinary Tract Infection Due To Klebsiella Species, Urinary Tract Infection Due To Proteus Species, Urinary Tract Infection Due To Pseudomonas Aeruginosa, Uti Due To Enterobacter Cloacae, Uti Due To Proteus Species, Uti Due To Pseudomonas Aeruginosa.

Dosing

Following reconstitution of the commercially available powders for injection containing a mixture of ceftazidime (as the pentahydrate) and sodium carbonate, solutions contain ceftazidime sodium; dosage of the drug is expressed in terms of anhydrous ceftazidime.

To avoid unintentional overdosage, the commercially available Duplex(R) drug delivery system containing ceftazidime and dextrose injection should not be used in patients who require less than the entire 1- or 2-g dose in the container.

In patients with renal impairment, doses and/or frequency of administration of ceftazidime should be modified in response to the degree of renal impairment, severity of the infection, and susceptibility of the causative organism. Excessive dosage and elevated plasma concentrations of the drug in patients with renal impairment can precipitate serious neurotoxicity (e.g., seizures, encephalopathy, coma, asterixis, neuromuscular excitability, myoclonia).

The manufacturers recommend that adults with creatinine clearances of 50 mL/minute or less receive an initial loading dose of 1 g of ceftazidime and a maintenance dosage based on the patient's creatinine clearance. (See Table 1.)

Table 1. Maintenance Dosage for Adults with Renal Impairment

Creatinine Clearance (mL/minute) Dosage 31-50 1 g every 12 h 16-30 1 g every 24 h 6-15 500 mg every 24 h <5 500 mg every 48 h

In patients with renal impairment and severe infections who would generally receive a ceftazidime dosage of 6 g daily if their renal function were normal, the manufacturers state that doses in the above table may be increased by 50% or the dosing frequency may be increased appropriately.

Alternatively, some clinicians recommend that adults with creatinine clearances of 30-80 mL/minute receive the usual doses of ceftazidime every 12-24 hours, adults with creatinine clearances of 10-29 mL/minute receive the usual doses every 24-36 hours, and adults with creatinine clearances less than 10 mL/minute receive the usual doses every 36-48 hours.

Because ceftazidime is removed by hemodialysis, a supplemental dose of the drug is generally indicated after each dialysis period. The manufacturers recommend that adults undergoing hemodialysis receive an initial 1-g loading dose of ceftazidime followed by a 1-g dose after each dialysis period.

In adults undergoing intraperitoneal dialysis or continuous ambulatory peritoneal dialysis, the manufacturers recommend that an initial 1-g loading dose of ceftazidime be given followed by a 500-mg dose every 24 hours. Some clinicians recommend that patients undergoing peritoneal dialysis receive 500 mg of ceftazidime every 24 hours and a supplemental 500-mg dose of the drug at the end of each dialysis period. If ceftazidime (as a sodium carbonate formulation) is administered intraperitoneally in the dialysis solution, the manufacturers recommend that 250 mg of the drug be added to each 2 L of dialysis solution.

In children with impaired renal function, the frequency of dosing should be decreased based on the degree of impairment.

Modification of the usual dosage of ceftazidime is generally unnecessary in patients with impaired hepatic function, unless renal function is also impaired.

Drug interactions

There is no enhanced messaging for this drug.

Contraindications

There is no enhanced messaging for this drug.

Adverse reactions

There is no enhanced messaging for this drug.

Precautions

No enhanced messaging available.

ICD codes

No ICD codes are available for this drug.

Formulary status

Search health-plan coverage for this drug by ZIP code.

Enter a 5-digit ZIP code. Searching does not change your profile.

Enter a ZIP code to view available health plans.

Last reviewed · Source: First Databank (FDB) drug data